215 related articles for article (PubMed ID: 16801406)
1. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil.
Zhou XJ; Fielman BA; Lloyd DM; Chao GC; Brown NA
Antimicrob Agents Chemother; 2006 Jul; 50(7):2309-15. PubMed ID: 16801406
[TBL] [Abstract][Full Text] [Related]
2. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects.
Zhou XJ; Lloyd DM; Chao GC; Brown NA
J Clin Pharmacol; 2006 Mar; 46(3):275-81. PubMed ID: 16490803
[TBL] [Abstract][Full Text] [Related]
3. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects.
Hu P; Jiang J; Wang H; Pietropaolo K; Chao GC; Brown NA; Zhou XJ
J Clin Pharmacol; 2006 Sep; 46(9):999-1007. PubMed ID: 16920894
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteers.
Fok BS; Gardner S; Piscitelli S; Chen S; Chu TT; Chan JC; Tomlinson B
Clin Ther; 2013 Jan; 35(1):68-76. PubMed ID: 23274144
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B.
He Z; Wang J; Liu K; Huang H; Du Y; Lin Z; Cai M; Feng X
Clin Res Hepatol Gastroenterol; 2012 Dec; 36(6):592-7. PubMed ID: 23069315
[TBL] [Abstract][Full Text] [Related]
6. Absence of a pharmacokinetic interaction between entecavir and adefovir.
Bifano M; Yan JH; Smith RA; Zhang D; Grasela DM; LaCreta F
J Clin Pharmacol; 2007 Oct; 47(10):1327-34. PubMed ID: 17675455
[TBL] [Abstract][Full Text] [Related]
7. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
[TBL] [Abstract][Full Text] [Related]
8. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications.
Zhou XJ; Lim SG; Lloyd DM; Chao GC; Brown NA; Lai CL
Antimicrob Agents Chemother; 2006 Mar; 50(3):874-9. PubMed ID: 16495245
[TBL] [Abstract][Full Text] [Related]
10. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
Lai CL; Leung N; Teo EK; Tong M; Wong F; Hann HW; Han S; Poynard T; Myers M; Chao G; Lloyd D; Brown NA;
Gastroenterology; 2005 Aug; 129(2):528-36. PubMed ID: 16083710
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Singal AK; Fontana RJ
Aliment Pharmacol Ther; 2012 Mar; 35(6):674-89. PubMed ID: 22257108
[TBL] [Abstract][Full Text] [Related]
12. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model.
Jacob JR; Korba BE; Cote PJ; Toshkov I; Delaney WE; Gerin JL; Tennant BC
Antiviral Res; 2004 Aug; 63(2):115-21. PubMed ID: 15302140
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of adefovir dipivoxil tablets in healthy Chinese volunteers.
Huang J; Zhang Y; Huang X; Li L; Li Y; Wang K; Yang J; He Y; Lv Y; Zheng Q
Int J Clin Pharmacol Ther; 2014 Jan; 52(1):8-14. PubMed ID: 24219967
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients.
Terrault NA; Tran TT; Schiff E; McGuire BM; Brown RS; Tupper R; Ramanathan S; Enejosa J; Zhong L; Zong J;
Liver Int; 2009 Sep; 29(8):1178-83. PubMed ID: 19486291
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.
Hézode C; Chevaliez S; Bouvier-Alias M; Roudot-Thoraval F; Brillet R; Zafrani ES; Dhumeaux D; Pawlotsky JM
J Hepatol; 2007 May; 46(5):791-6. PubMed ID: 17321635
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole.
Moore KH; Yuen GJ; Raasch RH; Eron JJ; Martin D; Mydlow PK; Hussey EK
Clin Pharmacol Ther; 1996 May; 59(5):550-8. PubMed ID: 8646826
[TBL] [Abstract][Full Text] [Related]
17. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
Mihm U; Gärtner BC; Faust D; Hofmann WP; Sarrazin C; Zeuzem S; Herrmann E
J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093
[TBL] [Abstract][Full Text] [Related]
18. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
Ohkawa K; Takehara T; Kato M; Kanada A; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Med Virol; 2009 May; 81(5):798-806. PubMed ID: 19319954
[TBL] [Abstract][Full Text] [Related]
19. Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration.
Kearney BP; Ramanathan S; Cheng AK; Ebrahimi R; Shah J
J Clin Pharmacol; 2005 Aug; 45(8):935-40. PubMed ID: 16027404
[TBL] [Abstract][Full Text] [Related]
20. Adefovir dipivoxil in the treatment of chronic hepatitis B.
Rivkin AM
Ann Pharmacother; 2004 Apr; 38(4):625-33. PubMed ID: 14990784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
